CHICAGO - s4story -- Braasch Biotech LLC, an emerging biopharmaceutical company pioneering a new field of anti-somatostatin vaccines, today announced a Notice of Allowance was received from the Japan Patent Office on July 15, 2025,  for Braasch's patent entitled "COMPOSITIONS FOR TREATMENT AND/OR PREVENTION OF MASTITIS."

The Patent Allowance provides claims for the therapeutic and preventative treatments for mastitis in milk production animals. Wherein the milk production animal exhibits significantly increased milk production within days of first vaccination, and does not exhibit loss of muscle mass, increased bone growth, injection site reaction, or hoof problems and decreased use of antibiotics.

The Braasch vaccine technologies, like other veterinary vaccines, utilize specific immunological responses post-vaccination. In the case of the Braasch vaccine, the endogenous hormone somatostatin is targeted. By attenuating the effects of this counter-regulatory hormone, a positive outcome is produced. Unlike other vaccines, the Braasch vaccine's mode of action is by B-cell epitope enhancements which produces an antibody response within 4 days (US Patent 10,441,652 B1, October 2019).

More on S For Story

• Open Art Call | The Art of Artificial Intelligence | Copenhagen
• Dylan Johnson Releases New Book - The Manipulator's Gambit
• Premieres of 10th Annual NY Dog Film Festival & 8th Annual NY Cat Film Festival on Sunday, October 26, 2025 to Benefit Animal Lighthouse Rescue
• $20 Price Target in Noble Capital Research Report as Deal is Signed for NFL Yearbook Advertising Across 25 Stadiums for AI Powered Sports Leader $SEGG
• 3E Launches First AI Agent Designed to Respond with Empathy for College Recruitment

"We are pleased that the Japan Patent Office has recognized the vaccine's novelty and commercial utility in the areas of mastitis treatment and milk production enhancement," stated Jeralyn Braasch Haffer, CEO.

Braasch's intellectual property portfolio includes multiple patent families with issued or pending claims directed to utility of anti-somatostatin vaccine technologies, SomatovacÔ for multiple metabolic challenges. These applications relate to both human and veterinary use of the technologies.

About Braasch Biotech

Braasch Biotech is a biopharmaceutical company with a focus on the development and commercialization of innovative products of therapeutic approaches utilizing SomatovacÔ technologies. Currently in the Product Pipeline are vaccines for livestock productivity enhancement, increased fertility, GH/IGF-1 deficiencies and obesity treatment. To date, Braasch has multiple regulatory submissions in progress on the use of vaccines in metabolic regulation of dairy cows, pigs and obese pets. Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota.

For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.